# Financial Results for FY2018 Second Quarter 

October 31, 2018

- SUMITOMO CHEMICAL


## (Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace;
Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## Contents

Financial Results for FY2018 Second Quarter
Financial Summary ..... 4
Sales revenue by Business segment ..... 5
Core Operating Income by Business segment ..... 6
Segment Analysis ..... 7
Breakdown of Non-recurring Items ..... 12
Consolidated Balance Sheets ..... 13
Consolidated Statements of Cash Flows ..... 14
Financial Estimates for Year ..... 15

## (Reference: Segment Information)

Cost Elements etc. ..... 17
Capital Expenditures by Business segment ..... 18 ..... 
Depreciation and Amortization by Business segment ..... 19
Research \& Development Expenses
by Business segment ..... 20
Sales revenue by Business segment (Quarterly) ..... 21
Core Operating Income by Business segment (Quarterly) ..... 22
Major Group Companies ..... 23

## Financial Results for FY2018 Second Quarter

© SUMITOMO CHEMICAL

## Financial Summary

Unit; billions of yen

|  | FY2017 2nd Quarter | $\begin{gathered} \text { FY2018 } \\ \text { 2nd Quarter } \end{gathered}$ | Difference | Ratio |
| :---: | :---: | :---: | :---: | :---: |
| Sales revenue | 1,040.3 | 1,122.1 | 81.8 | 7.9\% |
| Core operating income | 127.0 | 102.1 | -24.9 | -19.6\% |
| (Equity in earnings) | (22.7) | (23.9) | (1.2) | - |
| Non-recurring items | 9.1 | -10.2 | -19.3 |  |
| Operating income | 136.1 | 91.9 | -44.2 | -32.5\% |
| Finance income/expenses | 2.1 | 10.4 | 8.3 | - |
| (Gain/loss on foreign currency transactions) | (3.0) | (10.2) | (7.3) | - |
| Income tax expenses | -27.3 | -20.8 | 6.5 | - |
| Net income attributable to non-controlling interests | -33.8 | -20.0 | 13.8 | - |
| Net income attributable to owners of the parent | 77.1 | 61.5 | -15.6 | -20.2\% |
| ROE | 9.1\% | 6.4\% |  |  |
| Exchange rate(yen/\$) | 111.04 | 110.26 |  |  |
| Naphtha price(yen/KL) | 37,600 | 51,100 |  |  |
| Overseas sales revenue ratio | 63.4\% | 64.6\% |  |  |

## Sales revenue by Business segment

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference | Ratio | Sales <br> Price Variance | Shipping <br> Volume <br> Variance | Foreign Currency Conversion Variance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 320.1 | 380.4 | 60.3 | 18.8\% | 32.0 | 29.0 | -0.7 |
| Energy \& Functional Materials | 120.2 | 140.9 | 20.6 | 17.1\% | 8.0 | 12.1 | 0.5 |
| IT-related Chemicals | 188.5 | 195.4 | 6.9 | 3.6\% | -10.5 | 15.6 | 1.8 |
| Health \& Crop Sciences | 137.7 | 138.1 | 0.4 | 0.3\% | -0.5 | 4.4 | -3.4 |
| Pharmaceuticals | 248.1 | 242.7 | -5.4 | -2.2\% | -4.5 | -0.2 | -0.7 |
| Others \& Adjustments | 25.7 | 24.6 | -1.1 | -4.2\% | 0.0 | -1.1 | 0.0 |
| Total | 1,040.3 | 1,122.1 | 81.8 | 7.9\% | 24.5 | 59.7 | -2.4 |

## Analysis



## Core Operating Income by Business segment

Unit; billions of yen

|  | FY2017 2nd Quarter | FY2018 2nd Quarter | Difference | Price Variance | Cost Variance | Shipping Volume Variance and Other | Total |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 41.9 | 35.4 | -6.5 | -2.0 | 1.0 | -5.5 | -6.5 |
| Energy \& Functional Materials | 10.3 | 12.8 | 2.5 | -0.5 | -2.5 | 5.5 | 2.5 |
| IT-related Chemicals | 9.0 | 14.8 | 5.8 | -9.5 | 4.0 | 11.3 | 5.8 |
| Health \& Crop Sciences | 8.4 | 2.5 | -5.9 | -2.0 | -1.5 | -2.4 | -5.9 |
| Pharmaceuticals | 58.1 | 39.3 | -18.9 | -4.5 | -7.0 | -7.4 | -18.9 |
| Others \& Adjustments | -0.7 | -2.7 | -2.0 | 0.0 | 0.0 | -2.0 | -2.0 |
| Total | 127.0 | 102.1 | -24.9 | -18.5 | -6.0 | -0.4 | -24.9 |

## Analysis



## Petrochemicals \& Plastics - Segment Analysis -

## Sales revenue



## Total $¥ 380.4$ billion (+60.3 from FY2017 2nd Quarter )

Sales price +32.0

- Rise in market price
- Increase in shipment of Rabigh products

Foreign exchange -0.7

Core Operating Income Total ¥35.4 billion (-6.5 from FY2017 2nd Quarter )


Price variance
-2.0
Cost variance
$+1.0$
Volume variance etc. - Periodic plant maintenance in Chiba works
$-5.5$

- Decrease in profit margin on synthetic resins in overseas market
- Better profit margin on raw materials for MMA and synthetic fibers and Singapore
- Decrease in license revenue


## Energy \& Functional Materials - Segment Analysis -

## Sales revenue



## Total $¥ 140.9$ billion ( +20.6 from FY2017 2nd Quarter )

Sales price $+8.0$

Volume +12.1

- Higher market price for aluminum
- Increase in shipment of lithium-ion secondary battery separator
- Increase in shipment of cathode materials
- Increase in shipment of high purity alumina

Foreign exchange

$$
+0.5
$$

## Core Operating Income Total ¥12.8 billion (+2.5 from FY2017 2nd Quarter )

Price variance

$$
-0.5
$$

Cost variance
-2.5
Volume variance etc. - Increase in shipment of lithium-ion secondary battery separator

- Increase in shipment of high purity alumina


## IT-related Chemicals - Segment Analysis -

## Sales revenue



## Total $¥ 195.4$ billion ( +6.9 from FY2017 2nd Quarter )

Sales price -10.5

- Decline in selling price of polarizing film
- Decline in selling price of touchscreen panels

Volume +15.6

- Increase in shipment of polarizing film

Foreign exchange +1.8

## Core Operating Income Total $¥ 14.8$ billion ( +5.8 from FY2017 2nd Quarter )



## Health \& Crop Sciences - Segment Analysis -

## Sales revenue <br> 

## Total $¥ 138.1$ billion ( +0.4 from FY2017 2nd Quarter )

Sales price

$$
-0.5
$$

Volume +4.4

- Increase in shipment of crop protection chemical in overseas market

Foreign exchange
-3.4

## Core Operating Income Total ¥2.5 billion (-5.9 from FY2017 2nd Quarter)



Price variance
-2.0 Higher feedstock prices
Cost variance
-1.5

Volume variance etc. - Equity method investment loss on Nufarm
-2.4

## Pharmaceuticals - Segment Analysis -

Sales revenue


## Total ¥242.7 billion (-5.4 from FY2017 2nd Quarter )

Sales price -4.5
Volume -0.2

Foreign exchange -0.7

- NHI price revision in Japan
- Increase in shipment of Latuda® in North America
- Decrease in shipment of long-listed brands in Japan


## Core Operating Income Total ¥39.3 billion (-18.9 from FY2017 2nd Quarter )


Price variance

- NHI price revision in Japan
-4.5

Cost variance

- Increase in sales expense in North America
-7.0
- Increase in R\&D expense

Volume variance etc. - One time gain from divestiture of ciclesonide
-7.4 products in previous fiscal year

## Breakdown of Non-recurring Items

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: |
| Changes in fair value of contingent consideration | 4.1 | -6.9 | -10.9 |
| Restructuring charges | -1.4 | -2.4 | -1.0 |
| Gain on sale of property, plant and equipment | 6.8 | 0.0 | -6.7 |
| Others | -0.4 | -1.0 | -0.6 |
| Non-recurring items | 9.1 | -10.2 | -19.3 |

## Consolidated Balance Sheets

|  |  |  |  | Unit; billions of yen |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31-Mar-18 | 30-Sep-18 | Difference |  | 31-Mar-18 | 30-Sep-18 | Difference |
| Current assets | 1,254.8 | 1,343.9 | 89.0 | Liabilities | 1,816.5 | 1,928.8 | 112.3 |
| Cash and cash equivalents | 231.9 | 233.8 | 1.8 | Trade and other payables | 486.8 | 512.3 | 25.5 |
| Trade and other receivables | 530.6 | 555.3 | 24.7 | Interest-bearing Liabilities | 842.2 | 906.6 | 64.5 |
| Inventories | 446.8 | 489.9 | 43.1 | Others | 487.5 | 509.8 | 22.4 |
| Others | 45.5 | 64.9 | 19.4 | Equity | 1,252.2 | 1,335.1 | 82.9 |
| Non-current assets | 1,813.9 | 1,920.0 | 106.1 | Shareholders' equity | 842.0 | 882.8 | 40.8 |
| Property, plant and equipment | 675.7 | 731.3 | 55.5 | Other components of equity | 85.2 | 108.2 | 23.0 |
| Goodwill and Intangible assets | 355.5 | 372.9 | 17.5 | Non-controlling interests | 325.1 | 344.1 | 19.0 |
| Others | 782.6 | 815.7 | 33.1 |  |  |  |  |
| Total | 3,068.7 | 3,263.8 | 195.2 | Total | 3,068.7 | 3,263.8 | 195.2 |
|  |  |  |  | Equity attributable to owners of parent to total assets | 30.2\% | 30.4\% | 0.2\% |
|  |  |  |  | D/E ratio (times) | 0.7 | 0.7 | 0.0 |

## Consolidated Statements of Cash Flows

Unit; billions of yen

|  | FY2017 2nd Quarter | FY2018 2nd Quarter | Difference |
| :---: | :---: | :---: | :---: |
| Cash flows from operating activities | 115.8 | 55.6 | -60.2 |
| Cash flows from investing activities | -54.6 | -83.1 | -28.5 |
| Free cash flows | 61.2 | -27.5 | -88.7 |
| Cash flows from financing activities | -25.6 | 22.0 | 47.7 |
| Effect of exchange rate changes on cash and cash equivalents | 2.1 | 7.3 | 5.1 |
| Net change in cash and cash equivalents | 37.7 | 1.8 | -35.9 |
| Cash and cash equivalents at end of period | 231.0 | 233.8 | 2.7 |


|  | Unit; billions of yen |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 (Estimates) | Difference | Ratio |
| Sales revenue | 2,190.5 | 2,490.0 | 299.5 | 13.7\% |
| Core operating income | 262.7 | 240.0 | -22.7 | -8.6\% |
| (Equity in earnings) | (55.3) | (50.0) | (-5.3) | - |
| Operating income | 250.9 | 205.0 | -45.9 | -18.3\% |
| Net income attributable to owners of the parent | 133.8 | 130.0 | -3.8 | -2.8\% |
| ROE | 15.4\% | 13.4\% |  |  |
| Exchange rate(yen/\$) | 110.85 | 110.00 |  |  |
| Naphtha price(yen/KL) | 41,900 | 47,000 |  |  |

## (Reference: Segment Information)

## Cost Elements etc.

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: | ---: |
| Capital Expenditures | 64.6 | $\mathbf{8 8 . 8}$ | 24.2 |
| Depreciation and Amortization | 52.7 | $\mathbf{5 1 . 3}$ | -1.4 |
| Research \& Development Expenses | 78.4 | $\mathbf{8 0 . 6}$ | 2.2 |
| Number of Employees (as of September 30) | $\mathbf{3 1 , 8 5 8}$ | $\mathbf{3 2 , 3 9 9}$ | $\mathbf{5 4 1}$ |

## Capital Expenditures by Business segment

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 8.9 | 18.7 | 9.8 |
| Energy \& Functional Materials | 12.3 | 11.6 | -0.7 |
| IT-related Chemicals | 13.3 | 17.5 | 4.2 |
| Health \& Crop Sciences | 19.7 | $\mathbf{2 4 . 1}$ | 4.4 |
| Pharmaceuticals | 4.5 | $\mathbf{9 . 2}$ | 4.7 |
| Others \& Adjustments | 6.0 | $\mathbf{7 . 7}$ | 1.8 |
| Total | 64.6 | 88.8 | 24.2 |

## Depreciation and Amortization by Business segment

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference |
| :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 11.7 | 10.3 | -1.4 |
| Energy \& Functional Materials | 6.3 | 6.8 | 0.5 |
| IT-related Chemicals | 15.2 | 13.7 | -1.5 |
| Health \& Crop Sciences | 7.8 | 8.2 | 0.5 |
| Pharmaceuticals | 7.1 | 8.1 | 1.0 |
| Others \& Adjustments | 4.6 | 4.1 | -0.5 |
| Total | 52.7 | 51.3 | -1.4 |

## Research \& Development Expenses by Business segment

Unit; billions of yen

|  | FY2017 <br> 2nd Quarter | FY2018 <br> 2nd Quarter | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 3.2 | $\mathbf{3 . 2}$ | -0.1 |
| Energy \& Functional Materials | 4.0 | $\mathbf{3 . 9}$ | -0.1 |
| IT-related Chemicals | 8.4 | $\mathbf{9 . 1}$ | 0.7 |
| Health \& Crop Sciences | 13.9 | $\mathbf{1 4 . 2}$ | 0.3 |
| Pharmaceuticals | $\mathbf{4 1 . 7}$ | $\mathbf{4 2 . 5}$ | 0.8 |
| Others \& Adjustments | $\mathbf{7 . 3}$ | $\mathbf{7 . 9}$ | 0.6 |
| Total | $\mathbf{7 8 . 4}$ | $\mathbf{8 0 . 6}$ | $\mathbf{2 . 2}$ |

## Sales revenue by Business segment (Quarterly)


※ Quarterly figures for FY 2017 are not subject to financial review procedures at this moment.

## Core Operating Income by Business segment (Quarterly)


※ Quarterly figures for FY 2017 are not subject to financial review procedures at this moment.

## Major Group Companies

| Company | Sales Revenue |  | Profit Trends |
| :---: | :---: | :---: | :---: |
|  | $\begin{array}{c\|} \hline \text { FY2017 } \\ \text { 2nd Quarter } \end{array}$ | FY2018 |  |
| The Polyolefin Company (Singapore) (millions of USD) | 571 | 564 | Decreased margins and decreased sales volume due to periodic plant maintenance in the current term. |
| Petrochemical Corporation of Singapore (millions of USD) | 1,248 | 1,399 | Decreased sales volume due to periodic plant maintenance in the current term. |
| Rabigh Refining and Petrochemical Company <br> (millions of SAR) | 15,546 | 20,599 | Due to stable operations |
| Dongwoo Fine-Chem <br> (billions of KRW) | 1,113.0 | 1,143.7 | Increased due to higher sales volume and other factors despite lower selling price |
| Valent U.S.A. and Subsidiaries <br> (millions of USD) | 332 | 317 | Due to shipment timing difference and other factors |

